ANTX - NASDAQ

AN2 Therapeutics, Inc.

ANTX·NASDAQ

$4.17

+1.2%

HealthcareBiotechnology

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$114.27M

EPS-1.1600

P/E Ratio-3.59

Earnings Date08/06/2026

antx

Accounts Receivables

Last Annual Value

500.00K

3-Year CAGR

5-Year CAGR

10-Year CAGR

Adjust for Inflation

AN2 Therapeutics, Inc. Competitors Analysis of Accounts Receivables

ANTX · NASDAQ

Company	Accounts Receivables	CAGR 3Y	CAGR 5Y	CAGR 10Y
AN2 Therapeutics, Inc. NASDAQ:ANTX	500.00K	7.7%	N/A	N/A
Intensity Therapeutics, Inc. NASDAQ:INTS	0.00	N/A	N/A	N/A
Verrica Pharmaceuticals Inc. NASDAQ:VRCA	5.40M	8.3%	N/A	N/A
Q32 Bio Inc. NASDAQ:QTTB	0.00	N/A	N/A	N/A

AN2 Therapeutics, Inc. Fair Value Envelope

ANTX · NASDAQ

Our analysis suggests that ANTX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.17, this represents a potential HIDDEN relative to our calculated worth for AN2 Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $4.17

Related Guides

Blog Categories

Continue your ANTX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.